有害事象比較: Rosiglitazone vs Pioglitazone(アクトス)の直接比較

Rosiglitazone(商品名Avandia、アバンディア) vs Pioglitazone(アクトス)の直接比較



急性心筋梗塞  1.06 (95% 信頼区間l [CI], 0.96-1.18)
卒中 1.27 (95% CI, 1.12-1.45)
心不全 1.25 (95% CI, 1.16-1.34)
死亡 1.14 (95% CI, 1.05-1.24)
複合心筋梗塞・卒中・心不全・死亡  1.18 (95% CI, 1.12-1.23)

超過死亡寄与リスクは 100人年あたり 1.68 (95% CI, 1.27-2.08)
呼応するNNTHは、年あたり 60 (95% CI, 48-79)



JAMA Early Releases
for June 28, 2010

-----------------------------------------------------------------
Original Contributions
-----------------------------------------------------------------

Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in
Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
David J. Graham; Rita Ouellet-Hellstrom; Thomas E. MaCurdy; Farzana
Ali; Christopher Sholley; Christopher Worrall; Jeffrey A. Kelman
JAMA published 28 June 2010, 10.1001/jama.2010.920
http://jama.ama-assn.org/cgi/content/abstract/jama.2010.920v1?etoc



Rosiglitazone終了のお知らせ?

by internalmedicine | 2010-06-29 10:38 | 糖尿病・肥満  

<< STAR 3 研究:1型糖尿病... 高血圧治療における医師のマネー... >>